---
authors:
- ReactomeTeam
- Egonw
description: Phase 1 of metabolism is concerned with <i><b>functionalization</b></i>,
  that is the introduction or exposure of functional groups on the chemical structure
  of a compound. This provides a 'handle' for phase 2 conjugating species with which
  to react with. Many xenobiotics are lipophilic and almost chemically inert (e.g.
  PAHs) so would not necessarily undergo a phase 2 reaction. Making them more chemically
  reactive would facilitate their excretion but also increases their chance of reacting
  with cellular macromolecules (e.g. proteins, DNA). There is a fine balance between
  producing a more reactive metabolite and conjugation reactions.<br>There are two
  groups of enzymes in phase 1 - oxidoreductases and hydrolases. Oxidoreductases introduce
  an oxygen atom into or remove electrons from their substrates. The major oxidoreductase
  enzyme system is called the P450 monooxygenases. Other systems include flavin-containing
  monooxygenases (FMO), cyclooxygenases (COX) and monoamine oxidases (MAO). Hydrolases
  hydrolyse esters, amides, epoxides and glucuronides.  View original pathway at [http://www.reactome.org/PathwayBrowser/#DIAGRAM=211945
  Reactome].
last-edited: 2020-10-09
organisms:
- Homo sapiens
redirect_from:
- /index.php/Pathway:WP4085
- /instance/WP4085
schema-jsonld:
- '@context': https://schema.org/
  '@id': https://wikipathways.github.io/pathways/WP4085.html
  '@type': Dataset
  creator:
    '@type': Organization
    name: WikiPathways
  description: Phase 1 of metabolism is concerned with <i><b>functionalization</b></i>,
    that is the introduction or exposure of functional groups on the chemical structure
    of a compound. This provides a 'handle' for phase 2 conjugating species with which
    to react with. Many xenobiotics are lipophilic and almost chemically inert (e.g.
    PAHs) so would not necessarily undergo a phase 2 reaction. Making them more chemically
    reactive would facilitate their excretion but also increases their chance of reacting
    with cellular macromolecules (e.g. proteins, DNA). There is a fine balance between
    producing a more reactive metabolite and conjugation reactions.<br>There are two
    groups of enzymes in phase 1 - oxidoreductases and hydrolases. Oxidoreductases
    introduce an oxygen atom into or remove electrons from their substrates. The major
    oxidoreductase enzyme system is called the P450 monooxygenases. Other systems
    include flavin-containing monooxygenases (FMO), cyclooxygenases (COX) and monoamine
    oxidases (MAO). Hydrolases hydrolyse esters, amides, epoxides and glucuronides.  View
    original pathway at [http://www.reactome.org/PathwayBrowser/#DIAGRAM=211945 Reactome].
  keywords:
  - hydroxydocosahexaenoic acid
  - CYP1A1
  - NOHA
  - BaP4,5-DHD
  - LPAM
  - 5HT
  - '(2Fe-2S)2+ '
  - 'Zn2+ '
  - HBr
  - 'CYP11B2 '
  - 4HPAA
  - 'CYB5B '
  - HCPM
  - CYP11A1:FDXR:FDX1,FDX1L (red.)
  - L-Arg
  - '7'
  - PGH2
  - CORST
  - TES
  - CYP27A1
  - CHOL
  - (CYP2J2 based)
  - LTB4
  - 'CYP2C18 '
  - AOC3
  - FMO1:FAD
  - 4CHOL7a,24(S)DONE
  - CAF
  - PGG2
  - 'CYP11B1 '
  - 'CYP3A5 '
  - 20OH-TrXA3
  - 'Cu2+ '
  - 'NCOA1 '
  - resveratrol
  - (CYPIIIA4 based)
  - Phenytoin
  - LNSOL
  - EtOH
  - CCl4
  - 'ARNT2 '
  - POMC(138-176)
  - 'ADH1C '
  - 'CYP2C19 '
  - 'CYP2E1 '
  - PEA
  - 'AHRR '
  - ALDH3A1
  - BaP4,5O
  - (CYP3A5 based)
  - 'ADH6 '
  - 'PTGIS '
  - NADPH
  - SMOX-3
  - 4OH-9cRA
  - 'CYP2A7 '
  - 5HIALD
  - Hist
  - TAM
  - ATP
  - 'CYP4A22 '
  - 'CYP26B1 '
  - PTCN
  - (CYP4F11 based)
  - 'CYP8B1 '
  - 4CHOL7a,12a,27TONE
  - 24OH-CHOL
  - CES3
  - Phenylacetaldehyde
  - CYP3A43
  - diketone
  - ANDST
  - MTZ
  - 4-ethoxyaniline
  - NADH
  - HCOOH
  - TYLENOL)
  - NHABP
  - H2
  - CYP2U1
  - 'CYP4F12 '
  - 'FAD '
  - TBXAS1
  - (CYP2A3 based)
  - CYP2R1
  - acetyl group
  - ALDO
  - (CYP2A13 based)
  - TXA2
  - NASPM
  - 'CES1 '
  - RFDHN
  - 19OH-PGH2
  - DSQ
  - H+
  - 'PAOX '
  - PPi
  - 'CYP2A6 '
  - atRA
  - ACSS1
  - CBR3
  - 5'-monophosphate
  - (CYP4F3 based)
  - 'CYP4 '
  - CTLA
  - 'LCHA '
  - 'CYP4F11 '
  - 'AHR '
  - P4
  - 3AAPNAL
  - 'ADH1A '
  - '8,9-EET '
  - 'CYP26C1 '
  - AFB1
  - CMBL
  - 4CHOL7a,12aDONE
  - 'FDXR '
  - NADP+
  - E1
  - HPHAC
  - 'ADH4 '
  - AHRR:ARNT
  - 6BHT
  - 'MARC1 '
  - POR
  - (CYP7A1 based)
  - 'Mo-MPT '
  - TYR
  - Losec
  - (CYP4B1 based)
  - 9cRA
  - INDOL
  - PTGS1 dimer
  - 'FDX2 '
  - 'ARNT '
  - '11,12-EET '
  - PAOX:FAD
  - alcohol
  - H2O
  - 'CYP4F8 '
  - CYP26C1
  - '5,6-EET '
  - TrXA3
  - (CYP4F2/4F3 based)
  - DDCX
  - 'CYP2J2 '
  - 'CYP3A4 '
  - 12OH-DDCX
  - PREG
  - CYP4F22
  - BPHL
  - DHA
  - CYP11A1:FDXR:FDX1,FDX1L (ox.)
  - ALDH2 tetramer
  - 18HCORST
  - HDBQ
  - H2O2
  - NCOA1,2:RXRA:NR1H4:DCA,CDCA,LCHA
  - PHEN
  - 3,16DOH-PALM
  - NASPN
  - CHOL3b,7a,25TRIOL
  - 'CYP11A1 '
  - 4HPCP
  - Trichloromethyl
  - TMA
  - 12-HETE
  - 4CHOL7a,27DONE
  - ALDH1A1 tetramer
  - PhOH
  - FMO3:FAD
  - 'FDX1 '
  - CES1 trimer, CES2
  - (CYP2C9 based)
  - dimer:2xCu2+:4xCa2+
  - CYP1A2
  - 'DCA '
  - 'ALDH1A1 '
  - '(2Fe-2S)(1+) '
  - 11DCORT
  - 'heme b '
  - CTL
  - SPN
  - NH3
  - COUM
  - 'CYP26A1 '
  - 'Fe2+ '
  - (CYP4F12 based)
  - DOX
  - O2
  - 4OH-atRA
  - PTXL
  - 20OH-LTB4
  - I4AH
  - LCFA(-)
  - 'CYP2C8 '
  - TBM
  - CHOL7a,24(S)DIOL
  - ISCAL
  - 3MEIN
  - C2H4
  - adenosine
  - 'TCDD '
  - 'MAOB '
  - 'ALDH2 '
  - CoA-SH
  - AHR:TCDD:ARNT
  - HCOU
  - N-demethylated
  - 25(OH)D
  - receptor signalling
  - CYP46A1
  - TFAC
  - AOC1
  - CXPA
  - PGI2
  - (CYP2F1 based)
  - 'RXRA '
  - NAD+
  - CYP450:Fe3+
  - DEXT
  - BZAL
  - 'Fe3+ '
  - HPTXL
  - C6H6
  - CYP4V2
  - (CYP7B1 based)
  - 'NR1H4 '
  - 'CYP2S1 '
  - COCN
  - VACV
  - (CYP2B6 based)
  - (CYP2E1 based)
  - (CYP3A7 based)
  - HPHT
  - MIND
  - EPHX1
  - AMP
  - 'ALDH1B1 '
  - RFNA
  - AFXBO
  - AADAC
  - Ac-CoA
  - '14,15-EET '
  - EST17b
  - Acetaminophen (TN
  - CHEST
  - 'CYP4F3 '
  - dehydrogenase
  - 'CDCA '
  - CYP19A1
  - 4OH-EST17b
  - 'Mg2+ '
  - alpha-hydroxycholesterol
  - 'FMO3 '
  - ARA
  - CYP39A1
  - OLMS
  - 19HETE
  - 25OH-CHOL
  - (CYP11B1 based)
  - 'CYP4F2 '
  - SPM
  - (CYP8B1 based)
  - CYP2S1
  - CYP27B1(?-508)
  - AOC2
  - 'PTGS1 '
  - 'Ca2+ '
  - 'MARC2 '
  - Aryl hydrocarbon
  - CYP26A1,B1,C1
  - e-
  - VC
  - MTZ-SOX
  - 11DCORST
  - DOXOL
  - CH3COO-
  - 3OH-PALM
  - 'AOC1 '
  - 'MAOA '
  - MARC1:Mo-MPT:MARC2:Mo-MPT:CYB5B:CYB5R3
  - MLT
  - loperamide
  - quinone
  - 'ADH1B '
  - MAOB:FAD
  - cis-EET
  - CYP24A1
  - FMO2:FAD:Mg2+
  - BZAM
  - 'CYP4B1 '
  - 'ADH5 '
  - ACV
  - VD3
  - CYP1B1
  - ADH5:2xZn2+ dimer
  - ACSS2
  - Cl-
  - 'CES2 '
  - MAOA:FAD
  - CYP51A1
  - 4CHOL7aOLONE
  - 'CYP2D6 '
  - 'CYP2A13 '
  - 'CYP2F1 '
  - 'AOC3 '
  - CH3CHO
  - 'CYP3A7 '
  - (CYP2W1 based)
  - 4CHOL7a,12a,24(S)TONE
  - 'CYP4A11 '
  - HOMZ
  - S-FGSH
  - 18OH-ARA
  - hydroquinone
  - 'ADH7 '
  - 'FMO2 '
  - HTOLB
  - 'CYP2W1 '
  - complex
  - HALO
  - Cytochrome P450
  - CH2O
  - 'CYP3A43 '
  - 'CYP4F22 '
  - OM
  - 20a,22b-DHCHOL
  - 'CYP2B6 '
  - 'FMO1 '
  - ALDH1B1 tetramer
  - EtO
  - PTGIS,CYP8B1
  - CORT
  - (CYP2D6 based)
  - NQO2:FAD dimer
  - CYP11B2
  - 1,25(OH)2D
  - CYP450:Fe2+
  - 2CEO
  - CPM
  - S-HMGSH
  - 4,4DMCHtOL
  - 'NCOA2 '
  - (CYP4A11 based)
  - TAMO
  - 'CYP7A1 '
  - 3APAL
  - 'MyrG-CYB5R3(2-301) '
  - 'CYP7B1 '
  - radical
  - TMAO
  - 27OH-CHOL
  - CYP21A2
  - Paraxanthine
  - DEXM
  - L-Val
  - (CYP2C19 based)
  - 'NQO2 '
  - Oxindole
  - 'CYP2C9 '
  - (CYP2C18 based)
  - NABQI
  - MeOH
  - (CYP4F8 based)
  - ABPH
  - (CYP2C8 based)
  - BEG
  license: CC0
  name: Phase I - Functionalization of compounds
seo: CreativeWork
title: Phase I - Functionalization of compounds
wpid: WP4085
---